Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?

• We summarised immunosuppressing anticancer drugs which could worsen COVID 19 infections. • Other drugs were studied for drug-drug interactions with antiviral medicines. • A ready-to-use table synthesised these interactions between antiviral and anticancer drugs.

Detalles Bibliográficos
Autores principales: Gougis, Paul, Fenioux, Charlotte, Funck-Brentano, Christian, Veyri, Marianne, Gligorov, Joseph, Solas, Caroline, Spano, Jean-Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284279/
https://www.ncbi.nlm.nih.gov/pubmed/32610172
http://dx.doi.org/10.1016/j.ejca.2020.05.027
_version_ 1783544431207514112
author Gougis, Paul
Fenioux, Charlotte
Funck-Brentano, Christian
Veyri, Marianne
Gligorov, Joseph
Solas, Caroline
Spano, Jean-Philippe
author_facet Gougis, Paul
Fenioux, Charlotte
Funck-Brentano, Christian
Veyri, Marianne
Gligorov, Joseph
Solas, Caroline
Spano, Jean-Philippe
author_sort Gougis, Paul
collection PubMed
description • We summarised immunosuppressing anticancer drugs which could worsen COVID 19 infections. • Other drugs were studied for drug-drug interactions with antiviral medicines. • A ready-to-use table synthesised these interactions between antiviral and anticancer drugs.
format Online
Article
Text
id pubmed-7284279
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-72842792020-06-10 Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use? Gougis, Paul Fenioux, Charlotte Funck-Brentano, Christian Veyri, Marianne Gligorov, Joseph Solas, Caroline Spano, Jean-Philippe Eur J Cancer Article • We summarised immunosuppressing anticancer drugs which could worsen COVID 19 infections. • Other drugs were studied for drug-drug interactions with antiviral medicines. • A ready-to-use table synthesised these interactions between antiviral and anticancer drugs. Elsevier Ltd. 2020-09 2020-06-10 /pmc/articles/PMC7284279/ /pubmed/32610172 http://dx.doi.org/10.1016/j.ejca.2020.05.027 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Gougis, Paul
Fenioux, Charlotte
Funck-Brentano, Christian
Veyri, Marianne
Gligorov, Joseph
Solas, Caroline
Spano, Jean-Philippe
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
title Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
title_full Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
title_fullStr Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
title_full_unstemmed Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
title_short Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
title_sort anticancer drugs and covid-19 antiviral treatments in patients with cancer: what can we safely use?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284279/
https://www.ncbi.nlm.nih.gov/pubmed/32610172
http://dx.doi.org/10.1016/j.ejca.2020.05.027
work_keys_str_mv AT gougispaul anticancerdrugsandcovid19antiviraltreatmentsinpatientswithcancerwhatcanwesafelyuse
AT feniouxcharlotte anticancerdrugsandcovid19antiviraltreatmentsinpatientswithcancerwhatcanwesafelyuse
AT funckbrentanochristian anticancerdrugsandcovid19antiviraltreatmentsinpatientswithcancerwhatcanwesafelyuse
AT veyrimarianne anticancerdrugsandcovid19antiviraltreatmentsinpatientswithcancerwhatcanwesafelyuse
AT gligorovjoseph anticancerdrugsandcovid19antiviraltreatmentsinpatientswithcancerwhatcanwesafelyuse
AT solascaroline anticancerdrugsandcovid19antiviraltreatmentsinpatientswithcancerwhatcanwesafelyuse
AT spanojeanphilippe anticancerdrugsandcovid19antiviraltreatmentsinpatientswithcancerwhatcanwesafelyuse

Ejemplares similares